Lilly pipeline update lists brenipatide, macupatide and a long-acting GIP receptor agonist

Eli Lilly's public clinical development pipeline, current as of August 5, 2026, lists brenipatide, macupatide and a long-acting GIP receptor agonist, alongside eloralintide, which appears in Phase 3 testing for four separate uses ^[1]. The table shows which experimental molecules Lilly says it is studying and at what stage, but it does not include results, doses, trial sizes or timelines ^[1].

Eloralintide is listed as a new molecular entity in Phase 3 for obesity, and as being tested for obstructive sleep apnea, osteoarthritis pain and an "Eloralintide Incretin Add-On" for obesity that the company classifies as a new indication or line extension ^[1].

Brenipatide appears nine times on the table. Two of those entries are Phase 3, for alcohol use disorder and major depressive disorder. Seven are Phase 2, for asthma, bipolar disorder, irritable bowel syndrome with constipation, irritable bowel syndrome with diarrhea, opioid use disorder, schizophrenia and tobacco use disorder ^[1]. None of its listed programs are for obesity or diabetes ^[1].

Macupatide is listed once, as a Phase 2 new molecular entity for obesity ^[1]. A separate entry, "GIPR Agonist Long Acting," is in Phase 2 for chemotherapy-induced nausea and vomiting ^[1]. The table gives no further description of either molecule, such as how it works, how it would be taken or how far along its testing is beyond the phase label ^[1].

Other Lilly programs on the same page give context. Orforglipron appears under regulatory review for diabetes and in Phase 3 for cardiovascular outcomes, hypertension, obstructive sleep apnea, osteoarthritis pain, peripheral artery disease and stress urinary incontinence ^[1]. Tirzepatide is in regulatory review for cardiovascular outcomes and in Phase 3 for metabolic dysfunction-associated steatotic liver disease, morbidity and mortality in obesity, and type 1 diabetes, with a Phase 2 program studying higher doses ^[1]. Semaglutide does not appear on the table ^[1].

The company says Phase 1 projects are no longer disclosed and that some pipeline molecules are not identified for competitive reasons ^[1]. A disclaimer states that scientific and regulatory hurdles may cause pipeline molecules to be discontinued or delayed, or to fail to reach the market, and that there is no guarantee any of them will receive regulatory approval ^[1].

Why it matters for patients

The update does not change what is available at a pharmacy. Every molecule named in these newer entries is experimental, and the table itself carries Lilly's warning that pipeline molecules may never reach the market ^[1].

Eloralintide is the furthest along of the molecules highlighted in this update, with all four of its listed programs in Phase 3 ^[1]. Even so, Phase 3 status is not a guarantee of approval, and the page does not report how well the drug has performed in any study ^[1].

Macupatide and the long-acting GIP receptor agonist are in Phase 2, an earlier stage, and each is listed for a single use ^[1]. For readers whose main interest is weight or diabetes, macupatide is the more directly relevant of the two, while brenipatide's listed uses are mostly psychiatric, neurological and gastrointestinal conditions ^[1].

What is missing matters too. The table does not say how effective any of these molecules are, what side effects they cause, how they are dosed or how they compare with medicines already on the market, and those details have not been reported on the pipeline page ^[1].

What happens next

No dates for study completion, data readouts or regulatory filings for brenipatide, macupatide, the long-acting GIP receptor agonist or eloralintide's four programs appear on the table ^[1]. Lilly states that the information is current as of August 5, 2026 and that it assumes no duty to update it ^[1]. Because Phase 1 programs are no longer disclosed, earlier-stage work on these or other molecules is not visible ^[1], so it is not yet known when results might be announced.